Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART
- PMID: 17415038
- DOI: 10.1097/QAD.0b013e3280b0774a
Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART
Abstract
Objective: To compare the clinical, virological and immunological parameters of men and women at baseline and during antiretroviral treatment.
Methods: Analysis over time of data collected prospectively from of 2620 patients in a large cohort of HIV-infected patients followed for 12 months after initiating a nelfinavir-based antiretroviral regimen.
Results: Women had higher CD4 cell counts (P < 0.001), lower viral load (P < 0.001) and more favourable clinical profile (P < 0.001) than men at baseline. Following treatment, antiretroviral drug-naive women had higher CD4 cell count (P = 0.01) over time than drug-naive men but similar virological responses (P = 0.6); among drug-experienced individuals, women had also better immunological (P = 0.06) and similar virological (P = 0.3) responses compared with men. Consequently, the viroimmunological profile was significantly more favourable in women at each time point. The rates of clinical progression or death were also lower in women (P = 0.008), although drug toxicity was observed more commonly in women (P = 0.09). The highest viroimmunological responses were observed during the first 3 months of therapy in both sexes, although virological responses were achieved up to the 6th month in drug-naive patients. Sex was significantly associated with clinical (P = 0.01), virological (P = 0.01) and immunological (P = 0.006) responses to antiretroviral treatment in multivariate analyses after adjustment for other variables. The differences between genders were not explained by different adherence to therapy.
Conclusions: Women have more favourable clinical and viroimmunological patterns than men both at baseline and during antiretroviral treatment. Sex has a small but significant influence on the clinical and laboratory outcomes of HIV infection.
Similar articles
-
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.HIV Med. 2006 Mar;7(2):99-104. doi: 10.1111/j.1468-1293.2006.00347.x. HIV Med. 2006. PMID: 16420254
-
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7. Ned Tijdschr Geneeskd. 2001. PMID: 11534377 Clinical Trial. Dutch.
-
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.BMC Infect Dis. 2006 Jul 11;6:107. doi: 10.1186/1471-2334-6-107. BMC Infect Dis. 2006. PMID: 16834769 Free PMC article. Clinical Trial.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.Antivir Ther. 1999;4 Suppl 3:7-11. Antivir Ther. 1999. PMID: 16021865 Review.
Cited by
-
Determinants of virological failure among patients on first line highly active antiretroviral therapy (HAART) in Southwest Ethiopia: A case-control study.Front Public Health. 2022 Oct 25;10:916454. doi: 10.3389/fpubh.2022.916454. eCollection 2022. Front Public Health. 2022. PMID: 36408009 Free PMC article.
-
Sex-biased adaptive immune regulation in cancer development and therapy.iScience. 2022 Jul 4;25(8):104717. doi: 10.1016/j.isci.2022.104717. eCollection 2022 Aug 19. iScience. 2022. PMID: 35880048 Free PMC article. Review.
-
Asking the right questions: developing evidence-based strategies for treating HIV in women and children.BMC Public Health. 2011 May 25;11:388. doi: 10.1186/1471-2458-11-388. BMC Public Health. 2011. PMID: 21612633 Free PMC article.
-
Immunological and virologic outcomes of people living with HIV in Guangxi, China: 2012-2017.PLoS One. 2019 Mar 1;14(3):e0213205. doi: 10.1371/journal.pone.0213205. eCollection 2019. PLoS One. 2019. PMID: 30822343 Free PMC article.
-
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.AIDS. 2008 Nov 12;22(17):2291-302. doi: 10.1097/QAD.0b013e3283121ca9. AIDS. 2008. PMID: 18981768 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials